Overview

GnRHa for Luteal Phase Support in GnRH Antagonist Protocol Cycles

Status:
Recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
Evaluation of the effect of adding a single dose of gonadotropin releasing hormone agonist (GnRHa) as a luteal phase support on the outcomes of intracytoplasmic sperm injection (ICSI) following GnRH antagonist protocol
Phase:
Phase 4
Details
Lead Sponsor:
Mansoura University
Treatments:
Triptorelin Pamoate